HomeCompareIMGN vs EPRT

IMGN vs EPRT: Dividend Comparison 2026

IMGN yields 6.40% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $32.9K in total portfolio value· pulled ahead in Year 3
10 years
IMGN
IMGN
● Live price
6.40%
Share price
$31.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$962.44
Full IMGN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — IMGN vs EPRT

📍 EPRT pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMGNEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMGN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMGN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMGN
Annual income on $10K today (after 15% tax)
$544.26/yr
After 10yr DRIP, annual income (after tax)
$818.07/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,096.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMGN + EPRT for your $10,000?

IMGN: 50%EPRT: 50%
100% EPRT50/50100% IMGN
Portfolio after 10yr
$47.0K
Annual income
$6,901.58/yr
Blended yield
14.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

IMGN
Analyst Ratings
6
Buy
15
Hold
1
Sell
Consensus: Hold
Price Target
$14.79
-52.6% upside vs current
Range: $6.36 — $22.00
Altman Z
18.1
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMGN buys
0
EPRT buys
0
No recent congressional trades found for IMGN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMGNEPRT
Forward yield6.40%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$30.5K$63.4K
Annual income after 10y$962.44$12,840.73
Total dividends collected$8.1K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$14.79$35.50

Year-by-year: IMGN vs EPRT ($10,000, DRIP)

YearIMGN PortfolioIMGN Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,340$640.31$11,205$505.18+$135.00IMGN
2$12,813$678.62$12,672$682.46+$141.00IMGN
3← crossover$14,426$716.58$14,490$930.48$64.00EPRT
4$16,190$754.03$16,786$1,282.69$596.00EPRT
5$18,114$790.87$19,753$1,791.56$1.6KEPRT
6$20,209$826.97$23,677$2,541.64$3.5KEPRT
7$22,486$862.25$29,008$3,672.99$6.5KEPRT
8$24,957$896.64$36,463$5,425.08$11.5KEPRT
9$27,634$930.05$47,238$8,221.57$19.6KEPRT
10$30,531$962.44$63,385$12,840.73$32.9KEPRT

IMGN vs EPRT: Complete Analysis 2026

IMGNStock

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Full IMGN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this IMGN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMGN vs SCHDIMGN vs JEPIIMGN vs OIMGN vs KOIMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.